Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

7,662 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Context dependent effects of ascorbic acid treatment in TET2 mutant myeloid neoplasia.
Guan Y, Greenberg EF, Hasipek M, Chen S, Liu X, Kerr CM, Gackowski D, Zarakowska E, Radivoyevitch T, Gu X, Willard B, Visconte V, Makishima H, Nazha A, Mukherji M, Sekeres MA, Saunthararajah Y, Oliński R, Xu M, Maciejewski JP, Jha BK. Guan Y, et al. Commun Biol. 2020 Sep 7;3(1):493. doi: 10.1038/s42003-020-01220-9. Commun Biol. 2020. PMID: 32895473 Free PMC article.
Consequences of mutant TET2 on clonality and subclonal hierarchy.
Hirsch CM, Nazha A, Kneen K, Abazeed ME, Meggendorfer M, Przychodzen BP, Nadarajah N, Adema V, Nagata Y, Goyal A, Awada H, Asad MF, Visconte V, Guan Y, Sekeres MA, Olinski R, Jha BK, LaFramboise T, Radivoyevitch T, Haferlach T, Maciejewski JP. Hirsch CM, et al. Among authors: guan y. Leukemia. 2018 Aug;32(8):1751-1761. doi: 10.1038/s41375-018-0150-9. Epub 2018 May 24. Leukemia. 2018. PMID: 29795413 Free PMC article.
Invariant phenotype and molecular association of biallelic TET2 mutant myeloid neoplasia.
Awada H, Nagata Y, Goyal A, Asad MF, Patel B, Hirsch CM, Kuzmanovic T, Guan Y, Przychodzen BP, Aly M, Adema V, Shen W, Williams L, Nazha A, Abazeed ME, Sekeres MA, Radivoyevitch T, Haferlach T, Jha BK, Visconte V, Maciejewski JP. Awada H, et al. Among authors: guan y. Blood Adv. 2019 Feb 12;3(3):339-349. doi: 10.1182/bloodadvances.2018024216. Blood Adv. 2019. PMID: 30709865 Free PMC article.
A Therapeutic Strategy for Preferential Targeting of TET2 Mutant and TET-dioxygenase Deficient Cells in Myeloid Neoplasms.
Guan Y, Tiwari AD, Phillips JG, Hasipek M, Grabowski DR, Pagliuca S, Gopal P, Kerr CM, Adema V, Radivoyevitch T, Parker Y, Lindner DJ, Meggendorfer M, Abazeed M, Sekeres MA, Mian OY, Haferlach T, Maciejewski JP, Jha BK. Guan Y, et al. Blood Cancer Discov. 2021 Mar;2(2):146-161. doi: 10.1158/2643-3230.BCD-20-0173. Epub 2020 Dec 7. Blood Cancer Discov. 2021. PMID: 33681816 Free PMC article.
[No title available]
[No authors listed] [No authors listed] PMID: 34238758
TET2 mutations as a part of DNA dioxygenase deficiency in myelodysplastic syndromes.
Gurnari C, Pagliuca S, Guan Y, Adema V, Hershberger CE, Ni Y, Awada H, Kongkiatkamon S, Zawit M, Coutinho DF, Zalcberg IR, Ahn JS, Kim HJ, Kim DDH, Minden MD, Jansen JH, Meggendorfer M, Haferlach C, Jha BK, Haferlach T, Maciejewski JP, Visconte V. Gurnari C, et al. Among authors: guan y. Blood Adv. 2022 Jan 11;6(1):100-107. doi: 10.1182/bloodadvances.2021005418. Blood Adv. 2022. PMID: 34768283 Free PMC article.
Rare germline alterations of myeloperoxidase predispose to myeloid neoplasms.
Kongkiatkamon S, Terkawi L, Guan Y, Adema V, Hasipek M, Dombrovski T, Co M, Walter W, Awada H, Parker Y, Hutter S, Pagliuca S, Gurnari C, Rogers HJ, Meggendorfer M, Lindner DJ, Haferlach T, Visconte V, LaFramboise T, Jha BK, Maciejewski JP. Kongkiatkamon S, et al. Among authors: guan y. Leukemia. 2022 Aug;36(8):2086-2096. doi: 10.1038/s41375-022-01630-0. Epub 2022 Jun 27. Leukemia. 2022. PMID: 35761024
7,662 results